Global /United States /Healthcare /Drug Manufacturers - General /PTHS

Pelthos Therapeutics Inc.

PTHS

• NYSEAMERICAN: PTHS • Delayed

25.09USD 0.5%

As of 15 June 2026, Pelthos Therapeutics Inc. has a market cap of $84.19M USD, ranking #26764 globally and #4075 in the United States. It ranks #2398 in the Healthcare sector, and #865 in the Drug Manufacturers - General industry.

Global Rank

26764

Country Rank

4075

Sector Rank

2398

Industry Rank

865

Key Stats

Market Cap

$84.19MUSD

Enterprise Value

$101.05MUSD

Revenue (TTM)

$16.8MUSD

EBITDA (TTM)

-$29.12MUSD

Net Income (TTM)

-$43.32MUSD

EBITDA Margin

-173%

Profit Margin

-258%

PS Ratio

5.0

PB Ratio

2.1

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Scott Plesha open_in_new

Employees

Founded

2002

Website

pelthos.com open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.5%	9.1%	12%	1.6%	-23%	-19%	86%	-95%	-95%

News

PTHS Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NYSE American (NYSEAMERICAN / AMEX) MIC: XASE PRIMARY	PTHS Pelthos Therapeutics Inc ISIN: US1711262048 Shares Out.: Shares Outstanding: 3.476M¹ Shares Float: 2.826M² TV: TradingView: AMEX: PTHS SA: Stock Analysis: NYSEAMERICAN: PTHS YF: Yahoo Finance: PTHS GF: Google Finance: NYSEAMERICAN: PTHS NQ: NASDAQ: PTHS BA: Barron's: PTHS MS: Morningstar: XASE: PTHS	25.09 USD	TV: TradingView: AMEX: PTHS SA: Stock Analysis: NYSEAMERICAN: PTHS YF: Yahoo Finance: PTHS GF: Google Finance: NYSEAMERICAN: PTHS NQ: NASDAQ: PTHS BA: Barron's: PTHS MS: Morningstar: XASE: PTHS

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 905K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 650K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 428K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 325K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 177K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 140K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$320.51B 256.25B CHF 381K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 343K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$273.78B 218.9B CHF 325K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.97B 1.18T DKK 216K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 131K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 129K%	14.6	United Kingdom

chevron_leftBack